McKesson's first quarter revenue beats estimates at $105.4B, prompting a raise in FY27 EPS guidance.

McKesson reported first quarter fiscal 2027 revenue of $105.4 billion, an 8% year-over-year increase, and adjusted earnings of $9.93 per share, up 20%. The results surpassed analyst expectations for both revenue and profitability, leading the company to raise its full-year outlook.

Key Highlights

• Adjusted EPS increased 20% to $9.93, beating the $9.44 estimate.
• Full-year fiscal 2027 adjusted EPS guidance was raised to a range of $44.20 to $45.00, from the previous range of $43.80 to $44.60.
• Growth was led by the Oncology & Multispecialty segment, where revenue grew 33% to $14.2 billion, and the North American Pharmaceutical segment, where adjusted operating profit grew 19%.